A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

This study is testing a combination of adebrelimab (immunotherapy), apatinib (a drug that blocks blood vessel growth feeding the tumor), and chemotherapy as a pre-surgery (neoadjuvant) treatment for limited-stage small cell lung cancer — meaning the cancer is still confined to one area of the chest and may be surgically removable. **You may be eligible if...** - You are 18–75 years old - You have limited-stage small cell lung cancer confirmed by biopsy (T1–3 N0–1) - A surgeon, radiation oncologist, and radiologist have all agreed your tumor can be surgically removed - You have not had any prior treatment for this cancer - Your lung function and overall health are adequate **You may NOT be eligible if...** - You have already received any treatment for small cell lung cancer - You have another active cancer - Your lung function is significantly reduced - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.